Other substances

Irbesartan

An angiotensin II receptor antagonist.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Irbesartan on PubChem

Marketed as

APROVEL; AVAPRO; IFIRMASTA; IRBESARTAN; KARVEA; SABERVEL

 

Structure image - Irbesartan

CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5

Supporting references

Link Tested on Impact factor Notes Publication date
A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing
3CLpro Nucleocapsid protein nsp16 nsp10 Small molecule In silico 		in silico 2.74

Predicted to bind SARS-CoV-2 nsp10-nsp16 protein complex.

 Mar/18/2021

AI-suggested references

Link Publication date
ACE2 as a potential therapeutic target for pandemic COVID-19
Nov/01/2020
In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach
Feb/04/2020
Angiotensin II Promotes SARS-CoV-2 Infection via Upregulation of ACE2 in Human Bronchial Cells
May/04/2022
Export (.csv)